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Abstract
The crustacean Hyperglycemic Hormone (cHH) is present in many decapods in different isoforms, whose specific biological
functions are still poorly understood. Here we report on the first chemical synthesis of three distinct isoforms of the cHH of
Astacus leptodactylus carried out by solid phase peptide synthesis coupled to native chemical ligation. The synthetic 72
amino acid long peptide amides, containing L- or D-Phe
3 and (Glp
1, D-Phe
3) were tested for their biological activity by
means of homologous in vivo bioassays. The hyperglycemic activity of the D-isoforms was significantly higher than that of
the L-isoform, while the presence of the N-terminal Glp residue had no influence on the peptide activity. The results show
that the presence of D-Phe
3 modifies the cHH functionality, contributing to the diversification of the hormone pool.
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Introduction
The crustacean Hyperglycemic Hormone is a neuropeptide
synthesized and secreted by the X organ-sinus gland complex
(XO-SG) located in the eyestalks of decapod crustaceans. Its main
role concerns the regulation of the hemolymphatic glucose level,
but additional functions include growth control, reproduction, ion
balance, stress responses [1]. cHH belongs to a family of
crustacean peptides that includes the Molt Inhibiting Hormone
(MIH), the Vitellogenin Inhibiting Hormone (VIH) and the
Mandibular Organ Inhibiting Hormone (MOIH). All these
peptides are structurally related, having six conserved cysteines
that form three intramolecular disulfide bridges [2]. The family
can be further classified into two subfamilies on the basis of the
primary structure and the preprohormone peptide organization.
The cHH subfamily or type I possesses a cryptic sequence of
unknown function, named cHH precursor-related peptide, in the
unprocessed precursor [3], while the MIH/VIH/MOIH subfam-
ily or type II peptides that are longer and more variable in length,
have a Gly at position 12 and lack the cHH precursor-related
peptide [4] [5] [6]. Mature cHHs have a length of 72 to 73 amino
acid residues, and an homology among the different species
ranging from 40 to 99% [7]. They have an amidated C-terminus
and, in many cases, pyroglutamate as N-terminal blocking group
[1] [2]. Moreover, the phenylalanyl residue at position 3 of the
sequence can be found in either L- or D-configuration [8].
C-terminal amidation is the most significant post-translational
processing, because of its influence on cHH bioactivity, and the
lower functionality showed by non-amidated peptides can be
explained by a lower binding affinity to the cHH receptor due to
their negative C-terminus charge [9] [10].
Another post-translational modification concerns the cyclization
of the Glu residue at the N-terminal end, which is found in cHHs
of brachyuran crab species and crayfish, but not in shrimps [11].
The amino acid sequence of both N-terminus blocked and free
cHHs is almost identical, whereas the N-terminal residue can be
glutamine or pyroglutamate. In C. maenas both isoforms proved to
possess a similar biological activity and the same hemolymphatic
clearance rates. Thus seems that N-terminal cyclization has no
obvious biological function [12] [13], but it may well be that the
presence of a blocked N-terminus protects the cHH against
peptidases, extending its half-life like in other peptides [14].
D-amino acids have been found only in the peptides of some
invertebrates and amphibians. These include a toxin from a spider
venom, a snail neuropetide, some crustacean hormones of the
cHH family, and opiate and antimicrobial peptides from
amphibian skin [15]. To date L and D stereoisomers have been
reported only for the cHH of Astacoidea (Astacus leptodactylus,
Cherax destructor, H. americanus, Orconectes limosus, Procambarus bouvieri,
Procambarus clarkii), the stereoinversion concerning always the Phe
3
[16] [8] [17–20]. Little is known about the role of isomerization
and if the two stereoisomers have the same functions or exhibit
distinctive bioactivities. The presence of D-Phe
3 seems to confer a
higher hyperglycemic activity to the cHH. In an in vivo
heterologous bioassay, O. limosus was injected with L- or D-cHHA
extracted from SG of H. americanus, and purified by reverse-phase
high performance liquid chromatography (RP-HPLC). The peak
value of glycemia was in the same range for both isoforms,
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but the time course was different, with the D-cHHA inducing a
later response, having the maximal hyperglycemic peak at 3–4 h
instead of 2 h as for the L-cHHA, and a slower return to the base-
line, being the hyperglycemic effect still detectable at 8 h [8]. A
similar time course was found in A. leptodactylus after injection of
homologous D-cHH, purified by RP-HPLC from a sinus gland
extract, which induced a higher hyperglycemia and had an
extended response, the hemolymph glucose level being signifi-
cantly higher both at 3 h and 8 h, when compared to the
concentration elicited by the L-cHH. The same study proved that
cHH is involved in the control of osmoregulation, and that the
different stereoisomers may have different target tissues and/or
receptors. Indeed, all the purified cHHs were able to increase
hemolymph Na
+ concentration, but only D-cHH induced a
significant raise in hemolymph osmolality [19]. The higher
efficacy of the D isomer in exerting a biological activity was
proved also for the native cHH of P. clarkii, purified from the XO-
SG complex. In in vitro experiments it was shown that the cHH is
able to inhibit ecdysteroid biosynthesis in cultured Y-organs,
suggesting that this neuropetide may play a role in the crustacean
molting process. Of the two isoforms tested, the D-cHH showed a
ten fold higher inhibitory effect on ecdysteroidogenesis as well as
being more potent in inducing hyperglygemia [16]. On the
contrary, in the closely related Mexican crayfish P. bouvieri, whose
cHH share an identical amino acid sequence with those of P.
clarkii, the two isoforms showed the same ability to induce
hyperglycemia in destalked animals [17].
The present study describes the hyperglycemic activity of 3
analogues of cHH of the crayfish A. leptodactylus, prepared for the
first time by chemical synthesis, demonstrating the attractive
possibility to synthetically produce milligram amounts of cHH in a
specific desired form for future studies deciphering its functions.
Results
Peptide synthesis
The sequence of cHH1-72 and of its isomers (Fig. 1) contain
several potentially problematic sites for the SPPS with Fmoc/tBu
strategy. It contains six cysteine residues (prone to racemization),
nine aspartic acid residues (possible aspartimide formation,
followed by isomerisation, racemization and piperidide formation)
and a very hydrophobic region in the C-terminus part since 10
residues on the last 17 aa (56–72) are Leu, Ile, or Val (possible
poor couplings and Fmoc-deprotection, due to secondary structure
formation on the resin).
In our approach the sequence was divided in two parts, cHH1-
38 and cHH39-72 in order to use a native chemical ligation
reaction at Cys
39 to obtain the full length 72mer peptide (Fig. 1)
First, side chain and N-terminus Boc-protected cHH1-38 peptides
(Fig. 1, A) were synthesized by SPPS using Fmoc-methodology on
a very acid labile chlorotrityl resin. Second, protected peptide
carboxylic acids were cleaved from the resin with hexafluoroiso-
propanol (HFIP) in dichloromethane (DCM) (Fig. 1, B). At the end
(Fig. 1, C), the crude protected peptides were esterified to
corresponding 4-acetamidophenyl-thioesters, according to pub-
lished procedure [21]. After acid deprotection (Fig. 1, D), with
thiol free cleavage mixture, all 3 peptides thioaryl esters were
purified by RP-HPLC. C-terminal cHH39-72 peptide amide was
synthesized on Tentagel Sieber amide resin (Merck), a resin for
Fmoc SPPS derivatized by xanhydrylamine linker which gives
peptide amide fragments upon cleavage with trifluoroacetic acid
(TFA) [22]. After cleavage and deprotectection [TFA, triisopro-
pylsilane (TIPS), H2O, 3,6-dioxa-1,8-octanedithiol (DODT),
phenol, (81%/3%/3%/8%/5%) for 4 h] the C-terminal peptide
amide was purified by semipreparative RP-HPLC. The purity/
identity of all peptides was verified by liquid chromatography
electrospay ionization mass spectrometry (ESI-MS) (Table 1,
Fig. 2). Even though the synthesis of cHH39-72 went smoothly
(the purity of crude peptide was .55%), the deprotected and
purified peptide possesses a very low solubility in aqueous buffers
(due to its high hydrophobic AAs content), which complicates both
purification/recovery and followed step of NCL reactions (Fig. 1,
E). Despite the several solubilization conditions tried [guanidine
hydrochloride (GuHCl), urea, sodium dodecyl sulfate, 2,2,2-
trifluoroethanol, HFIP, and its mixtures] a substantial cHH39-
72 precipitation occurred in all NCL conditions tested, negatively
affecting the final yields of purified and folded (see experimental
part) cHH1-72 isomers. Different approaches such as introducing
on C-terminus solubilizing cleavable tails are actually under
evaluation. Purified linear 72 amino acids long peptides were
folded (Fig. 1, F) in basic condition in the presence of oxidized/
reduced glutathione or Cys/Cys2 and purified to homogeneity by
RP-HPLC with yields between 1 and 3%.
Bioassays
The biological assays on A. leptodactylus were performed as time-
course experiments to assess potential biological activity differenc-
es among the three chiral isoforms of the synthetic peptide (Fig. 1,
1, 2 and 3) and to compare them to the native hormone. The two
chiral synthetic isoforms of cHH showed significant different
hyperglycemic responses in term of both time course/kinetic
pattern and absolute values of circulating glucose (Fig. 3).
Injection of 1.7 pmol/g live weight of each of the three analogue
peptides revealed the following results: synthetic D-cHH induced a
quick hyperglycemic response already detectable after 1 h and a
strong hyperglycemic response with the maximum peak of
95.468.1 mg/dL glucose after 4 h, high values lasting at 8 h
(76612.1 mg/dL) and glycemia returning to its nearby basal level,
8.961 mg/dL, after 24 h (Fig. 3, a). Glp-D-cHH mirrored the time
course of D-cHH, with the strongest hyperglycemic response of
96.165.6 mg/dL glucose after 4 h, high values lasting at 8 h
(62.9611.8 mg/dL) and the glycemia returning to its basal level,
2.960.5 mg/dL, after 24 h (Fig. 3, c). L-cHH induced a lower
hyperglycemic response with the maximumpeak of 5266.5 mg/dL
glucose after 2 h, and the glycemia returning to its nearby basal
level, 5.560.4 mg/dL, after 8 h (Fig. 3, b). Injection of the purified
SG-cHH was comparable to that of the synthetic L-cHH, the
maximum (4464.5 mg/dL) being reached after 2 h, and the
glycemiareturningtoitsbasallevel,561.1 mg/dLafter24 h(Fig.3,
d).The comparison oftheglycemiaelicitedby eachof the analogues
during the first 8 hours post-injection revealed significant differ-
ences between time points (Kruskal-Wallis p,0.01) and the
Bonferroni adjusted p values of post-hoc pairwise comparisons at
different times compared to initial values were significant. At 24 h,
only the hyperglycemia induced by the D-cHH was still significantly
different from that of time 0 h. The comparison among the
glycemic values elicited by the different peptides 4 or 8 hours post-
injection revealed significant differences (4 h – Kruskal-Wallis chi-
squared=29.5491, df=3, p=1.72?10
26 ***; 8 h – Kruskal-Wallis
chi-squared=21.7912, df=3, p=7.209?10
25 ***). The Bonferroni
adjusted p values of post hoc pairwise comparisons revealed two
peptide groups, D-cHH and Glp-D-cHH on one hand eliciting
significantly higherglycemicresponsethanL-cHHandSG-cHHon
the other hand. To evaluate the overall hyperglycemic potentiality
of the three synthetic peptides and the native one, the maximum
values recorded in the experiments for each specimen from 1 h to
8 h were plotted in Fig. 4. The D-cHH and the Glp-D-cHH (means
Functionality of Synthetic CHH Stereoisomers
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showed again their higher capacity to mobilize the glucose
compared to both L-cHH and SG-cHH (means of max glycemia
of, respectively, 52.464 and 52.769.4 mg/dL).
Discussion
The cHH plays a major role in controlling the hemolymphatic
glucose level, but it also has significance in regulating molt,
reproduction and homeostasis, nevertheless the putative distinct
functions exerted by the different circulating cHH forms are still
poorly understood. To study the biological role of the cHH family
peptides, large amounts of them are required, and in the past years
different approaches were tried in order to obtain sufficient
peptide quantities. To achieve this purpose different technologies
were used: extraction from natural sources [23] [24] [25],
production by recombinant DNA technology [26] [27] [10], and
by chemical synthesis [28].
The purification of native neuropeptides by RP-HPLC has a
low yield, about 2–4 mg (270–489 pmol) per sinus gland in C.
maenas [29], but the invaluable advantage is to obtain naturally
folded peptides, complete of all the post-translational modifica-
tions. DNA recombinant technology proved to be useful to obtain
crustacean peptides in greater quantities to enable further
investigation of their physiological functions. Recombinant cHHs
from Metapenaeus ensis [30], Nephrops norvegicus [31], Penaeus japonicus
[9], Macrobrachium rosenbergii [32], and A. leptodactylus [10], were
produced using bacterial expression systems. All these works
reported the insertion of fusion tags for purification of target
proteins by affinity chromatography. These additional sequences
may interfere with the receptor binding which results in a lowered
biological activity [9]. Moreover, recombinant peptides are never
Figure 1. Scheme of the SPPS coupled to NCL to obtain the full length peptides. The leading segments containing a C-terminal thioester,
QVF-cHH4-38, QVdF-cHH4-38, pEVdF-cHH4-38, and the cHH39-72 following segment with a free N-terminal cysteine were synthesized by SPPS. The
NCL reaction between the leading and following segments returned the full length 72mer cHH isomers, which were further subjected to oxidative
folding to obtain the folded peptides.
doi:10.1371/journal.pone.0030052.g001
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functionality. Therefore, this important post-translational modifi-
cation must be added later through a specific enzymatic reaction
[9] [10], while another post-translational modification, the
pyroglutamilation of the N-terminus, is prevented by the presence
of N-terminal tags. To overcome the problems posed by peptide
expression in Escherichia coli, an eukaryotic expression system was
developed. The cHH from Penaeus monodon was successfully
expressed in the yeast Pichia pastoris, from which it was secreted
to the culture medium already correctly refolded, and from it
directly purified by RP-HPLC. The recombinant Pem-cHH was
capable of inducing hyperglycemia in eyestalk-ablated prawns,
although with a lower potency compared with the native peptide,
due probably to the lack of C-terminal amidation [33].
Chemical synthesis enables a level of control on protein
composition that greatly exceeds that attainable with ribosome-
mediated biosynthesis, allowing post-translational modifications
like C- and N-terminus blockage and insertion of D-amino acids,
while native chemical ligation allows to overcome the limit of the
peptide length posed by SPPS [34]. This approach was applied to
synthesize the MIH from P. clarkii. The synthetic peptide was
comparable to the sinus gland extracted Prc-MIH in the inhibition
of ecdysteroid secretion by in vitro cultured Y-organs [28].
Our study was aimed at the production of several isoforms of
the cHH of A. leptodactylus, by means of SPPS coupled with the
native chemical ligation, in order to verify the effect that N-
terminus pyroglutamylation and isomerization of the Phe
3 have on
peptide functionality through in vivo homologous bioassays.
Changes in amino acid chirality add more variety to the pool of
synthesized peptides. The presence of a D-amino acid may lead to
structural modifications as the peculiar type II9b-turn structure
found in the snail Gly-D-Phe-Ala sequence of achatin I [35] or the
b-turn of amphibian opioid peptides that is involved in the
receptor recognition [36]. The L-isomers of these peptides do not
bind to the corresponding receptors, thus having no biological
function. In other cases D-peptides were found to be far more
potent in eliciting a biological response. Frog dermorphin, when
injected into the rat brain, is about one thousand more potent then
morphine in inducing long-lasting analgesia [37]. This behaviour
may be also the result of a resistance to peptidases, as L-
dermorphin is rapidly degraded, while the D-peptide is not
hydrolyzed [15].
Our study shows that D-cHH was more potent than L-cHH in
inducing glycemia, with a quick response detectable after 1 h and
the maximum peak of 95.468.1 mg/dL glucose after 4 h from
injection. On the contrary, L-cHH had its maximum peak at 2 h
after injection, with hyperglycemic peak of 5266.5 mg/dL. The
superiority of D-cHH over the L-counterpart is probably due to a
change in the secondary structure of the peptide that may increase
the cHH affinity for receptors located on its target organs. This
behavior is in agreement with previous studies. Indeed, D-cHH
purified from SG of A. leptodactylus exhibited a higher hypergly-
cemic response compared to the L-isomer [19]. The hyperglyce-
mic effect triggered by D-cHH was extended in time: the glycemia
recorded at 24 h was still significantly elevated (p=1.1?10
23)
respect to basal levels (time 0). This result is surprising, if we
consider that cHH is cleared from the hemolymph quite
dynamically, being of 10 min the half life reported in C. maenas
[38]. The prolonged effect could be due to a slower dissociation
constant from the receptor, as consequence of the conformational
variation in 3D structure of D-isomers, or due to a higher
resistance to peptidases. A low, but significant hyperglycemia at
24 h after injection with native D-cHH was already found in A.
leptodactylus [19], an effect corroborated by our findings. The
different hyperglycemic time-course of the L and D isomers was
also shown in a heterologous bioassay, where the injection of D-
cHH from H. americanus into O. limosus produced a longer
hyperglycemic response than that caused by equal doses of L-
cHH, even if the maximal hyperglycemic responses were
comparable [8]. The Glp-D-cHH was more potent than the N-
terminus blocked native hormone of A. leptodactylus, inducing a
higher hyperglycemic outcome. Native cHH circulates in the
hemolymph as a mixture of L- and D-isoforms, of which the D-
cHH is the less abundant, in C. destructor amounting to 30–40% of
the L-isoform [20]. The hemolymph content of cHH reflects the
ratio of cells synthesizing the two isomers. In the X-organ of the
crayfish O. limosus, a cluster of approximately 30 cells producing
cHH was identified, of which only about 8 cells synthesize the D-
cHH [18]. Therefore, it is conceivable that the minor activity of
the native peptide extract was due to the higher proportion of the
L-isoform which, as we have seen, has a lower activity. Our results
show that the isomerization of the Phe
3 affects the cHH
functionality modifying its capability to mobilize the glucose
reserves, and being cHH a pleiotropic hormone involved, besides
glucose regulation, in secretion of digestive enzymes [39], lipid
metabolism [40], osmoregulation [19] [41], growth [29] [42], and
reproduction [43] [44], it can be also assumed that the two
isoforms may play different roles in various physiological contexts.
In the crayfish P. clarkii both stereoisomers exhibit hyperglycemic
activity, but the D-isomer showed a more potent inhibition of
ecdysteroid synthesis in in vitro cultured Y-organ [16]. The
involvement of cHH in the control of osmoregulation was proved
in the crab P. marmoratus where cHH extracted from SG increased
the Na
+ influx in perfused posterior gills from crabs acclimated to
diluted seawater [45]. The ability of this neuropeptide to exert an
effect on osmolality and Na
+ concentration of the hemolymph was
Table 1. ESI-MS data of cHH analogues (1–3), thioesters (1a–3a) and cHH (39–72)-amide.
cHH (1–72) cHH aryl thioester (1–38) cHH (39–72)-amide
calc.(av.)/found (Da) calc.(av.)/found (Da) calc.(av.)/found (Da)
1 L-Phe
3-cHH: 1a QVF-cHH-4-38:
8407.7/8406.0 4670.4/4669.2
2 D-Phe
3-cHH: 2a QVf-cHH-4-38: 3904.5/3903.0
8407.7/8406.2 4670.4/4669.9
3 Glp-D-Phe
3-cHH: 3a pEVf-cHH-4-38:
8390.7/8385.0 4653.4/4651.2
doi:10.1371/journal.pone.0030052.t001
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cHH raised both hemolymph osmolality and Na
+ concentration
after 24 h, while L-cHH had no significant effect on osmolality,
but increased Na
+ concentration, however with a lower rise [19].
Besides isomerization, we studied the effect of another post-
translational modification, pyroglutamylation from the N-terminal
glutamine residue of cHH. It has been already proved in crabs that
pyroglutamyl-blocked and unblocked cHHs exhibited identical
Figure 2. RP-HPLC profiles and ESI-MS spectra of the synthesized cHH isomers. Reverse Phase HPLC profiles of the purified refolded
synthetic polypeptides and their corresponding ESI-MS multiply charged ion and deconvoluted spectra (insets): L-Phe
3-cHH (A and B), D-Phe
3-cHH (C
and D), Glp-D-Phe
3-cHH (E and F). Mobile Phase A: 0.1% TFA in water. Mobile Phase B: 0.1% TFA in MeCN. Gradient: 0–100% B over 25 min. Column:
Gemini 5 C18 2.06150 mm.
doi:10.1371/journal.pone.0030052.g002
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oidogenesis in vitro, and showed similar clearance/degradation
rates in the hemolymph. Both cHH variants are present in the
sinus glands at a constant ratio, the blocked cHH being the major
form, and the same proportion is maintained in the hemolymph
[12]. In a study of the biosynthesis of cHH performed as time-
course experiments with pulse-chase incubations, on in vitro
cultured X-organ SG complexes from O. limosus, cyclization
resulted incomplete as glutaminyl L-cHH represented about 30%
of the blocked peptide. Because cyclization of 70–80% of the cHH
occurs within 8 h, then remaining constant, it was supposed that
this modification is catalyzed by a putative glutaminyl cyclase
during the axonal transport [46]. Our results confirm the
bioactivity data already found in crabs, because the hyperglycemic
activity showed by blocked cHH, Glp-D-cHH, was not signif-
icantly different (p.0.9) at any time of the time course from that of
D-cHH, whose N-terminus is free. The similar behavior of these
two forms suggests that the pyroglutamate block at the N-terminus
has no biological function, at least with respect to hyperglycemic
activity or to peptide half-life, though it is widely accepted that N-
terminal blocked peptides are more resistant to aminopeptidases
[14].
Among the protein post-translational modifications, which
enrich the diversity of the peptides encoded by the same gene,
the fascinating modification of chirality is the less understood. Our
data indicate that SPPS coupled to native chemical ligation is a
suitable strategy for the synthesis of crustacean peptides of the
cHH family, being the only one that allows the introduction of all
Figure 3. Time course of the induced glycemia after injection of the synthetic and wild type cHHs. a) Time course of hemolymph
glycemia after injection of 1.7 pmol/g live weight of D-cHH. The maximum peak of 95.468.1 mg/dL glucose is reached after 4 h, high values lasting
at 8 h (76612.1 mg/dL), when the maximum values were also recorded, and the glycemia returning to its nearby basal level, 8.961 mg/dL, after
24 h. N=20. b) Time course of hemolymph glycemia after injection of 1.7 pmol/g live weight of L-cHH. L-cHH induced a slower hyperglycemic
response with the maximum peak of 5266.5 mg/dL glucose after 2 h, and the glycemia returning to its nearby basal level, 5.560.4 mg/dL, after 8 h.
N=16. c) Time course of hemolymph glycemia after injection of 1.7 pmol/g live weight of Glp-D-cHH. The time course of Glp-D-cHH shows the
stronger hyperglycemic response of 96.165.6 mg/dL glucose after 4 h, high values lasting at 8 h (62.9611.8 mg/dL) and the glycemia returning to
its basal level, 2.960.5 mg/dL, after 24 h. N=9. d) Time course of hemolymph glycemia after injection of 1.7 pmol/g live weight of SG-cHH. The
hyperglycemic time course after the injection of 1.7 pmol/g live weight of purified SG-cHH was comparable to that of synthetic D-cHH and Glp-D-
cHH peptides, but the maximum (4464.5 mg/dL) was reached after 2 h and the glycemia returning to its basal level, 561.1 mg/dL after 24 h. N=9.
doi:10.1371/journal.pone.0030052.g003
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identical to the native hormone, and therefore it is an appropriate
alternative to DNA recombinant technology. The optimization of
the present synthesis protocol can make available cHH peptides
for large scale in vivo and in vitro experiments that could lead to a
better understanding of cHH role and structure-activity relation-
ships.
Materials and Methods
Reagents
9-Fluorenylmethoxycarbonyl (Fmoc) protected amino acid
building blocks were ordered from Novabiochem, Bachem, and
Fluka. Resins for SPPS were from Novabiochem and Fluka.
Benzotriazol-1yl-oxy-tris-(pyrrolidino)-phosphonium-hexafluoro-
phosphate (PyBOP) and 2-(6-Chloro-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) acti-
vators were from NovaBiochem. Anhydrous N,N9-dimethylfor-
mamide (DMF) and DCM were from Romil; phenol was from
AnalR; piperidine (PIP) and HFIP were from IRIS Biotech; N-
diisopropylethylamine (DIPEA) and TFA were from Biosolve;
TIPS from Alfa Aesar; DODT, diethylether, petroleum ether
and dichloroethane (DCE) were from Sigma; 4-acetamidothio-
phenol (HSPhNHAc) was from Merck.
Peptide synthesis
Peptides were synthesized at 0.1 mmol scale by solid phase
method using Fmoc/tBu chemistry. Both N- and side chains
protected peptide carboxylic acids from N-terminal sequence of
cHHs (1–38) were assembled on Fmoc-Thr(But)-TGT-resin
(Fluka, substitution ,0.2 mmoles/g). cHH39-72 amide was
synthesized at 0.3 mmol scale on TentaGel Sieber amide resin
(Novabiochem, 0.2 mmol/g).
Side chain protecting groups were: Trityl (Trt for Asn, Cys,
Gln), t-Butyl (tBu for Ser, Thr), t-Butyloxycarbonyl (Boc for Lys,
Tyr, Trp), tert-Butylester (OtBu for Asp, Glu), 2,2,4,6,7-penta-
methyldihydro-benzofuran-5-sulfonyl (Pbf for Arg). The Fmoc
amino acid (four molar excess with respect to the initial resin
substitution), the coupling reagent (HCTU), and the base
(DIPEA), in a ratio of 1:1:2, were dissolved in DMF to give a
final amino acid concentration of 0.3 M. Systematic double
coupling was adopted to add residues using PyBOP as coupling
reagent instead of HCTU. Fmoc protecting groups were removed
by a 20% (v/v) solution of PIP in DMF containing 0.1 M 1-
hydroxybenzotriazole to decrease aspartimide formation. In order
to minimize Cys racemization, 4 equivalents for 2 h of Fmoc-
Cys(Trt)-OPfp in DMF was employed in the first coupling. The
second coupling was performed for 1 h with four molar excess of
Fmoc-Cys(Trt)-OH, HCTU, 2,6-dimethylpyridine, in 1:1:2 ratio
as a 0.3 M solution in DCE/DMF 1:1 (v/v), as described [47].
Cleavage and side chain deprotection of cHH39-72 peptide
amide resin was performed for 4 h with 20 mL/g resin of TIPS/
H2O/DODT/phenol/TFA (3%/3%/8%/5%/81%), followed by
precipitation and washing with diethyl ether and drying. Crude
cHH39-72 peptide amide were reduced by 10 molar excess tris(2-
carboxyethyl)phosphine (TCEP) in 0.1 M Tris pH 8 with 6 M
GuHCl and purified by semipraparative RP-HPLC (Jupiter C4
106250 mm, Phenomenex) using 0.5% gradient slope from 0.1%
TFA in water (mobile phase A) to 0.1% TFA in 98% acetonitrile
(MeCN) (mobile phase B).
Cleavage of all three protected cHH1-38 peptide isoforms was
performed separately by 33% HFIP in DCM (4 times with 2 resin
volume for 15 min). The solvents were evaporated, the rest was
washed with Et2O/hexane (1/3) and dried. Thioester formation
of cHH1-38 isoforms was performed according published
procedure [21]. Briefly, 200 mg (,0.027 mmol) each of protected
cHH1-38 was suspended in 1 ml DCM containing 27.9 mg
(0.216 mmol, 8 eq.) DIPEA, mixed for 2 min at room temperature
under nitrogen, then cooled to 4uC; dry PyBop 56.2 mg
(0.108 mmol, 4 eq.) was added, mixed vigorously for 0.5 min
and then 22.7 mg (0.135 mmol, 5 eq.) dry HSPhNHAc (purity
.99%, freshly prepared by TCEP reduction) was added under
nitrogen. The reaction mixture was vigorously mixed for
additional 4 min and then occasionally in total for 2 h. The
solvent was evaporated and the rest (oil) was mixed with 3 ml
Et2O and 6 ml petroleum ether, the solid was centrifuged, washed
again with 2 ml petroleum ether and dried in vacuo. The crude
peptide thioesters were fully deprotected for 3 h with H2O/TIPS/
Phenol/TFA (2.5%/2.5%/5%/90%, 20 mL/g resin) and then
precipitated/washed with diethyl ether. The crude peptide
thioesters were dissolved and purified by semipreparative RP
HPLC as described above. Pure (according ESI-MS, API 150EX,
ABSciex) fractions were pooled and feeze-dried.
Native chemical ligation
The native chemical ligations of the thioester peptides cHH1-38
with cHH39-72 were performed dissolving the two peptide
components at concentration ,5–10 mg/mL in ligation buffer
[(0.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
6 M GuHCl, 50 mM TCEP, 20 mM ethylenediaminetetraacetic
acid (EDTA)] at pH 6.8–7.0. The N-terminal peptide was used in
slight molar excess (,10%) with respect to the counterpart. The
reactions went overnight at RT under gentle stirring.
Purification and oxidative folding
The NCL reaction mixtures were analyzed by LC-MS and
purified by RP-HPLC in two different mobile phase systems.
Linear reduced L-cHH and D-cHH were purified from the NCL
mix by RP-HPLC using the classical acidic (0.1% TFA) mobile
phase system on a semipreparative column Jupiter C4
106250 mm (Phenomenex) using a gradient of 0.5% B/min and
the product was eluted at ,40% MeCN. The pure fractions
Figure 4. Boxplots of the maximum glucose values recorded
for the synthetic and native peptides. Both D-cHH and Glp-D-cHH
induced a strong hyperglycemia with a mean peak glucose concentra-
tion of, respectively, 100.569.3 and 98.766 mg/dL, while the hyper-
glycemic effect of GS-cHH and of L-cHH was lower, with a mean of max
glycemia of 52.769.4 mg/dL and of 52.466.4 mg/dL respectively.
doi:10.1371/journal.pone.0030052.g004
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freeze dried. The peptides were re-dissolved at 0.1 mg/ml and
subjected to oxidative folding in 0.25 M Tris-HCl, 5 mM reduced
glutathione, 1 mM oxidized glutathione, 1 mM EDTA buffer
adjusted at pH 8 under argon. The refolded L-cHH and D-cHH
were purified by RP-HPLC on a semipreparative column Jupiter
C4 106250 mm using a gradient of 0.5% B/min. The product
was eluted at ,38% MeCN. The Glp-D-cHH NCL reaction
mixture was instead purified using the same column but in neutral
pH conditions (Mobile Phase A was 20 mM triethylammonium
acetate in water, Mobile Phase B was 20 mM triethylammonium
acetate, 80% acetonitrile) and a gradient of 0.75% B/min from
15% to 60% B. Pure (according to ESI-MS) fractions were pooled
and freeze-dried. Purified (according to ESI-MS) fraction of Glp-
D-cHH at pH 7 was diluted to 0.1 mg/mL, directly folded by air
oxidation overnight under gentle stirring and then freeze dried.
The loss of 6 Da in the molecular masses indicating the
completeness of the three disulfide bonds formation was verified
by ESI-MS in all cases.
Extraction and purification of native Asl-cHH
Sinus glands from 40 eyestalks of A. leptodactylus were collected
and 100 mL of extraction solution (90% MetOH, 9% acetic acid,
1% H2O) was added. After sonication, the sample was centrifuged
at 12 0006 g for 10 min at 4uC, and the supernatant collected.
The pellet was resuspended in 100 mL of the extraction solution,
centrifuged again, and the two supernatants were mixed together.
The extract was purified on a HPLC system (Gilson) equipped
with a Zorbax SB-C18 4.66150 mm column from Agilent
Technologies Inc. (DE, USA) thermostated at 25uC. Mobile
Phase A was 0.1% TFA in water, Mobile Phase B was 0.1% TFA
in acetonitrile. The separation was done using a gradient of 0–
100% B in 60 min at 1 mL/min. Collected fractions were
analysed on a API150EX single quadrupole mass spectrometer
(ABSciex), and those containing the expected molecular mass of
8383.5 Da, corresponding to the peptide with N-terminus
pyroglutamate, were pooled and liophylised.
Biological assays with cHH isoforms
Adult A. leptodactylus, with an average weight of 4165,9 g, were
obtained from a local dealer. The animals were kept in 120 L
tanks with closed circuit filtered and thoroughly aerated tapwater,
at room temperature. Animals were fed with fish pellets three
times per week. Crayfish were anesthetized in ice for 15 min and
then bilaterally eyestalk ablated 48 h before the start of the
experiment, in order to avoid any possible interference due to the
endogenous cHH. To assay the hyperglycemic activity, lyophilized
RP-HPLC fractions of synthetic or native peptides were
resuspended in 50 mL sterile phosphate buffered saline (PBS).
Peptide concentration was determined by UV absorbance at
280 nm using calculated e values of 14815 M
21 cm
21 for the
peptide oxidized form. The extinction coefficient was computed
using the ProtParam programme on the ExPASy server [48]. Each
animal was treated with a peptide amount equal to 1.7 pmol/g
live weight. Before injection, peptide samples were diluted with
sterile PBS and 100 mL of this solution was injected. Animals were
bled at 0, 1, 2, 4, 8 and 24 h after injection. Hemolymph glucose
level was quantified using the glucose oxidase method (One Touch
glucose test kit – Lifescan).
Statistics
For glycemia elicited at the various times, the normality of data
was checked with a Shapiro-Wilk test and homogeneity of
variance for each time across groups and for each peptide across
times were checked with a Bartlett test. Analyses were conducted
using non-parametric statistics, i.e. Kruskal-Wallis rank sum test
with post-hoc Wilcoxon rank sum test pairwise comparisons with
Bonferroni correction, since the null hypothesis of the Shapiro
Wilk and/or the Bartlett tests could not be rejected. The box and
whiskers plots were drawn with the boxplot command. In the text,
values are expressed as mean 6 standard error. Statistical analyses
were performed using R version 2.9.2 software [49].
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